$ 1344.00
Fulvestrant-Resistant MCF7 Breast Cancer Cells (MCF7/182R-6)
Payment Options
We accept Visa and MasterCard in our online store.
Worldwide Shipping
We can get your purchases to you wherever you are.
Customer Care
As an Axol customer you have access to our support team and product specialists.
Description
MCF7/182R-6 is a fulvestrant-resistant MCF7 breast cancer cell line. The parental MCF7/S0.5 line was treated long-term with 100 nM fulvestrant and the surviving clone was expanded as a resistant cell line. To maintain a high level of resistance, the cells are cultured in the presence of 100 nM fulvestrant.
Condition of sale: the end user is not permitted to transfer or re-freeze the cells.
Product Specification
| Donor gender | Female |
| Donor age at sampling | 69 yrs |
| Genetic modification | None |
| Size | 1 million cells |
| Growth properties | Adherent |
| Disease information | Malignant adenocarcinoma derived from pleural effusion |
| General notes | Expresses the estrogen receptor (ER); resistant to fulvestrant at 100 nM |
| Shipping conditions | Dry ice |
| Storage conditions | Liquid nitrogen |
| Usage notes | Culture in DMEM/F12 medium (no phenol red) supplemented with 1% fetal bovine serum + 2.5 mM GlutaMAX + 6 ng/mL insulin. Addition of 100 nM fulvestrant is required to maintain a high level of resistance |
| Condition of sale | The end user is not permitted to transfer or re-freeze the cells |
Technical Resources
References
- Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. International Journal of Cancer (1995)
- Nabha SM, Glaros S, Hong M et al. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene (2005)
- Frogne T, Jepsen JS, Larsen SS. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocrine-related Cancer (2005)
- Frankel LB, Lykkesfeldt AE, Hansen JB. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Research and Treatment (2007)
- Frogne T, Benjaminsen RV, Sonne-Hansen K. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Research and Treatment (2009)
- Sonne-Hansen K, Norrie IC, Emdal KB. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Research and Treatment (2010)
- Thrane S, Pedersen AM, Thomsen MB et al. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Oncogene (2015)